Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers Meeting Abstract


Authors: Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; Ladanyi, M.; Hyman, D. M.; Sirulnik, L. A.; Drilon, A.
Abstract Title: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Meeting Title: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Journal Title: Molecular Cancer Therapeutics
Volume: 18
Issue: 12 Suppl.
Meeting Dates: 2019 Oct 26-30
Meeting Location: Boston, MA
ISSN: 1535-7163
Publisher: American Association for Cancer Research  
Date Published: 2019-12-01
Language: English
ACCESSION: WOS:000510047200443
DOI: 10.1158/1535-7163.Targ-19-pr02
PROVIDER: wos
Notes: Meeting Abstract: PR02 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jean Marie Torrisi
    16 Torrisi
  2. Marc Ladanyi
    1328 Ladanyi
  3. David Hyman
    354 Hyman
  4. Romel Somwar
    111 Somwar
  5. Eileen O'Reilly
    782 O'Reilly
  6. Alexander Edward Drilon
    633 Drilon
  7. Alison Michele Schram
    123 Schram
  8. Rym Benayed
    188 Benayed